Antimicrobial Agents and Chemotherapy最新文献

{"title":"The entire <i>CYP51B</i> locus in azole-resistant isolates of the dermatophyte <i>Trichophyton indotineae</i> revealed by optical genome mapping.","authors":"Tsuyoshi Yamada, Mari Maeda, Minami Nakagawa, Takashi Yaguchi, Masaki Ishii, Karine Salamin, Christine Pich-Bavastro, Michel Monod","doi":"10.1128/aac.01817-25","DOIUrl":"10.1128/aac.01817-25","url":null,"abstract":"<p><p>The resistance of <i>Trichophyton indotineae</i> to azoles is mainly due to the overexpression of <i>TinCYP51B,</i> resulting from additional copies of this gene in two types of strains (type I and type II). Due to its large size and the significant number of duplicated blocks, whole-genome sequencing has been unable to cover the entire <i>TinCYP51B</i> locus. Through optical genome mapping (OGM), we have successfully determined the copy number of the <i>TinCYP51B</i> gene in the genomes of resistant strains. The <i>TinCYP51B</i> copy number was lower in the type I strains than in the type II strains, while the <i>TinCYP51B</i> expression level was higher in the type I strains. To explain this paradox, we have revealed that polycistronic transcription of multiple <i>TinCYP51B</i> open reading frames (ORFs) alongside monocistronic transcription occurs in type I azole-resistant strains. In contrast, type II strains generated only the transcripts encoding one CYP51B polypeptide. OGM has also revealed that a 970 kb region on chromosome 3 is inverted in type I strains and the azole-susceptible strain TIMM20115, as compared to type II strains and the azole-susceptible strain TIMM20114. This has led to the hypothesis that under azole stress, type I resistant strains originate from susceptible strains such as TIMM20115, which possesses a single <i>TinCYP51B</i> gene. Conversely, it is believed that type II azole-resistant strains evolve from susceptible strains such as TIMM20114, which also has only one <i>TinCYP51B</i> gene. In conclusion, strains of <i>Trichophyton indotineae</i> can be divided into two groups in which a distinct type of resistance has developed.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0181725"},"PeriodicalIF":4.5,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification of outcomes in antimalarial therapeutic efficacy studies with Aster.","authors":"Inna Gerlovina, Sophie Berube, Jessica Briggs, Kathryn Murie, Maxwell Murphy, Amy Wesolowski, Bryan Greenhouse","doi":"10.1128/aac.01411-25","DOIUrl":"10.1128/aac.01411-25","url":null,"abstract":"<p><p>Reliable assessment of antimalarial drug efficacy is crucial for an effective response to emerging drug resistance, and therapeutic efficacy studies (TESs) are the primary means of estimating <i>in vivo</i> efficacy. The accuracy of such estimates rests on correctly classifying recurrent infections developed during follow-up as recrudescences or new infections. Genotyping is used to guide classification, but polyclonal infections and alleles matching by chance make classification challenging, especially in high transmission settings. Match-counting algorithms currently recommended by the World Health Organization are unreliable and produce biased results, necessitating the development of principled statistical approaches. Modern genotyping methods, such as multiplexed amplicon sequencing, hold great potential for resolving recurrences and motivate the need for corresponding statistical methods able to utilize the rich data they provide. We propose an Adaptive Statistical framework for Therapeutic Efficacy and Recrudescence (Aster) that delivers accurate and consistent results by explicitly incorporating the complexity of infection, population allele frequencies, and imperfect detection of alleles in minority strains. Using an identity-by-descent approach, Aster accounts for alleles matching by chance and for a background infection relatedness structure that can otherwise lead to misclassification. The flexible framework can also use external information, such as parasite density and performance characteristics of a genotyping panel. Using simulations, we show that Aster dramatically outperforms match-counting algorithms in a wide variety of transmission settings and demonstrates consistently balanced performance that improves with more informative genotyping panels. Aster is implemented in a fast, fully scalable, and user-friendly R software package, <i>asterTES,</i> and provides accurate estimates of treatment failure for TES with any type of genotyping data, facilitating reliable evaluation of drug efficacy and effective management of malaria.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0141125"},"PeriodicalIF":4.5,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147669838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and characteristics of a novel fosfomycin glutathione transferase, FosA12, from an MDR clinical isolate of <i>Proteus vulgaris</i>.","authors":"Wei Lu, Lihong Li, Xi Lin, Dongxin Liu, Keqing Zhang, Xinxin Zhou, Daojun Yu, Shenghai Wu","doi":"10.1128/aac.01138-25","DOIUrl":"10.1128/aac.01138-25","url":null,"abstract":"<p><p>This study identifies <i>fosA12</i>, a novel chromosomally encoded fosfomycin resistance gene in a multidrug-resistant <i>Proteus vulgaris</i> clinical isolate. Through whole-genome sequencing, <i>fosA12</i> was characterized, showing 64.23% homology with <i>Pseudomonas aeruginosa</i>'s <i>fosA</i>. FosA12, a glutathione S-transferase, confers high-level fosfomycin resistance (MIC 512 μg/mL) via five critical residues. These findings highlight <i>fosA12</i>'s role in resistance and the need for clinical surveillance.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0113825"},"PeriodicalIF":4.5,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147687548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptome-constrained genome-scale metabolic modeling reveals central carbon and amino acid metabolic reprogramming underlying colistin-sulbactam synergy in <i>Acinetobacter baumannii</i>.","authors":"Xingchen Bian, Yan Zhu, Xiaofen Liu, Xin Li, Wanzhen Li, Jinxin Zhao, Jian Li, Jing Zhang","doi":"10.1128/aac.01848-25","DOIUrl":"https://doi.org/10.1128/aac.01848-25","url":null,"abstract":"<p><p>This study aimed to construct a genome-scale metabolic model (GSMM) for <i>Acinetobacter baumannii</i> and integrate transcriptomic data from colistin, sulbactam, and their combination to delineate the mechanism of synergistic metabolic perturbations. A GSMM of <i>A. baumannii</i> 163560 was reconstructed with CarveMe and curated using literature and Biolog assays. Transcriptomic data under different antibiotic treatments were integrated with the model using RIPTiDe, and flux variability analysis was conducted to identify metabolic perturbations across monotherapies and combination therapies. The curated model (2,103 reactions, 1,492 metabolites, and 1,033 genes) achieved prediction accuracies of 80% for gene essentiality and 80.5% for carbon source utilization. Transcriptomic constraints substantially reduced the active network across all treatments while retaining core pathways such as the TCA cycle and amino acid metabolism. Colistin uniquely activated the glyoxylate cycle, consistent with a stress-adaptive bypass of central carbon metabolism. In contrast, the colistin-sulbactam combination induced distinct shifts toward amino acid, nucleotide, and ion metabolism, with aspartate-related pathways showing characteristic flux increases. Flux variation analysis further demonstrated enhanced TCA cycle activity under colistin and combination therapy, likely reflecting an oxidative stress response. Combination treatment also revealed unique essential reactions involving nucleotide and amino acid biosynthesis. Colistin and sulbactam elicit distinct metabolic rewiring in <i>A. baumannii</i>. Combination therapy drives a shift from central carbon metabolism toward amino acid and ion metabolism. Enzymes such as isocitrate lyase, malate synthase, and aspartate deaminase-absent in mammals-represent potential targets to enhance synergistic antibacterial effects.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0184825"},"PeriodicalIF":4.5,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of VIM-1-producing <i>Enterobacter</i> spp. across Switzerland: clonal dissemination and plasmid transmission.","authors":"Helena M B Seth-Smith, Mariella Greutmann, Jacqueline Findlay, Christiane Beckmann, Livia Berlinger, Silvio D Brugger, Riccarda Capaul, Gilbert Greub, Eva Gruner, Peter M Keller, Oliver Nolte, Tim Roloff, Sarah Tschudin-Sutter, Walter Zingg, Patrice Nordmann, Laurent Poirel, Adrian Egli","doi":"10.1128/aac.01827-25","DOIUrl":"https://doi.org/10.1128/aac.01827-25","url":null,"abstract":"<p><p>Carbapenemase-producing Enterobacterales (CPE) are a major public health concern. Within the <i>Enterobacter cloacae</i> complex (ECC), the <i>bla</i>_VIM-1 carbapenemase gene is frequently plasmid-borne, enabling inter-clonal and inter-species spread that complicates the detection and control of carbapenemase dissemination. We investigated an increase in VIM-1-producing <i>Enterobacter</i> spp. reported to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) between 2022 and 2024 using high-resolution genomic methods. Between January 2022 and October 2024, <i>bla</i>_VIM-1-positive <i>Enterobacter</i> spp. isolates from 39 patients, plus additional contemporary <i>bla</i>_VIM-1-positive Enterobacterales, were analyzed. Whole-genome sequencing (Illumina) was performed for all isolates, with long-read sequencing (Oxford Nanopore Technologies) for 12 selected isolates. Species identification, genomic relatedness by MLST and cgMLST, and fine-scale plasmid characterization and comparison were performed. Most isolates were <i>Enterobacter hormaechei</i> (<i>n</i> = 37), alongside <i>Enterobacter kobei</i> (<i>n</i> = 1) and <i>Enterobacter ludwigii</i> (<i>n</i> = 1), distributed across 13 sequence types, excluding purely clonal dissemination. Hybrid assemblies showed <i>bla</i>_VIM-1 located on several plasmid types. IncHI2 plasmids of 249-343 kb carrying additional antimicrobial resistance promoting genes including <i>mcr-9</i> predominated, spanning multiple ECC lineages and also present in two other species. Conjugation of these was confirmed experimentally, and within-host plasmid variation was observed. No further cases occurred after October 2024. We describe a multiclonal spread of <i>bla</i>_VIM-1 Enterobacterales in Switzerland, mediated by IncHI2 plasmids. These findings highlight the need for plasmid-focused genomic surveillance to complement clonal typing in CPE outbreak investigations.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0182725"},"PeriodicalIF":4.5,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empirical glycopeptide exposure and acute kidney injury during cloxacillin therapy in <i>Staphylococcus aureus</i> bacteremia.","authors":"Miguel Ángel Verdejo, Daniela Malano-Barletta, Cristina Pitart, Marta Hernández-Meneses, Guillermo Cuervo, Marta Bodro, Carolina García-Vidal, Néstor Lopez, Sabina Herrera, Ana Del Río, Mateu Espasa, Climent Casals, Josep Mensa, Laura Morata, Alex Soriano","doi":"10.1128/aac.00128-26","DOIUrl":"https://doi.org/10.1128/aac.00128-26","url":null,"abstract":"<p><p>We aimed to identify risk factors for the development of acute kidney injury (AKI) during treatment of <i>Staphylococcus aureus</i> bacteremia (SAB), with particular emphasis on the roles of cloxacillin and cefazolin, and the contribution of other antibiotics. We performed a retrospective, observational, single-center study of a prospective cohort of patients with SAB receiving cloxacillin or cefazolin as definitive therapy and with serum creatinine available at baseline and days 5, 10, and 15. The primary outcome was the highest AKI stage between days 5 and 15; the secondary outcome was 30 day mortality. Univariate and multivariate analyses were performed to identify independent predictors of outcomes. A total of 470 patients were included in the study, and 103 (21.9%) developed AKI during hospitalization. Independent predictors of AKI were age >64 years (adjusted odds ratio [aOR] 1.76; 95% CI 1.08-2.87), peripheral arterial disease (aOR 2.23; 95% CI 1.02-4.88), chronic kidney disease (aOR 3.77; 95% CI 2.07-6.89), need of mechanical ventilation (aOR 3.33; 95% CI 1.62-6.86), and cloxacillin as definitive treatment with prior glycopeptide exposure (aOR 3.45; 95% CI 1.74-6.84). AKI occurred in 42.6% (23/52) of patients receiving empirical glycopeptide followed by cloxacillin, compared with 21.0% (61/290) in those treated with cloxacillin without prior glycopeptide exposure. The development of AKI during admission was an independent predictor of 30 day mortality (aOR 3.50; 95% CI 1.88-6.52). The only modifiable factor associated with AKI was the use of cloxacillin as definitive therapy after prior exposure to glycopeptides. These data reinforce the need to consider non-nephrotoxic alternatives.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0012826"},"PeriodicalIF":4.5,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical failure of an extended-pulsed fidaxomicin regimen associated with emergence of a <i>Clostridioides difficile</i> isolate with reduced fidaxomicin susceptibility in an elderly man.","authors":"Claire E Kaple, Sarah N Redmond, Jennifer L Cadnum, Bryan Hausman, Munok Hwang, Hosoon Choi, Piyali Chatterjee, Chetan Jinadatha, Curtis J Donskey","doi":"10.1128/aac.00130-26","DOIUrl":"https://doi.org/10.1128/aac.00130-26","url":null,"abstract":"<p><p>The clinical significance of <i>Clostridioides difficile</i> isolates with reduced fidaxomicin susceptibility is uncertain. We report treatment failure of extended-pulsed fidaxomicin treatment during every other day pulsing associated with emergence of a <i>C. difficile</i> isolate with reduced fidaxomicin susceptibility and a novel <i>rpoC</i> gene mutation, resulting in a novel amino acid substitution (R89K). The reduced susceptibility isolate had no reduction in growth or ability to colonize mice, but <i>in vitro</i> sporulation and toxin production were reduced.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0013026"},"PeriodicalIF":4.5,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Chirumbolo, \"Antimicrobial regimens for the treatment of pan-drug-resistant <i>Acinetobacter baumannii</i> infections: some comments\".","authors":"Konstantinos Pontikis, Ilias Karaiskos, Helen Giamarellou, George L Daikos","doi":"10.1128/aac.00107-26","DOIUrl":"https://doi.org/10.1128/aac.00107-26","url":null,"abstract":"","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0010726"},"PeriodicalIF":4.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam.","authors":"Jun Morita, Kazuya Ishiwata, Shogo Matsumoto, Ignacio Rodriguez, Katie Patel, Gemma Attley, Navita L Mallalieu, Darren Bentley","doi":"10.1128/aac.00113-26","DOIUrl":"https://doi.org/10.1128/aac.00113-26","url":null,"abstract":"<p><p>Nacubactam is a novel bicyclic non-β-lactam β-lactamase inhibitor that acts as a penicillin-binding protein (PBP-2) active antibacterial, almost exclusively cleared by renal excretion. This study assessed the effect of renal function and hemodialysis on nacubactam pharmacokinetics following a single intravenous (IV) 1 g infusion. Part 1 included three subjects with normal renal function, and six each with mild, moderate, or severe renal impairment; Part 2 included eight subjects with end-stage renal disease undergoing hemodialysis. We observed a strong linear relationship between renal function and both nacubactam total clearance and renal clearance. Compared with subjects with normal renal function, mean nacubactam total clearance was 49%, 73%, and 85% lower among subjects with mild, moderate, and severe renal impairment, respectively, and renal clearance was 42%, 70%, and 90% lower. Nacubactam systemic exposure was correspondingly greater in subjects with impaired renal function. Compared with the normal renal function group, AUC_0-inf was 2-fold, 3.7-fold, and 6.6-fold higher in the mild, moderate, and severe impairment groups, respectively. Similar results were observed across four different methods of estimating renal clearance. Nacubactam was cleared by hemodialysis, with more than 60% of a single dose eliminated during a 4-h dialysis session. Renal impairment had no apparent effect on the safety profile of nacubactam, and a single 1 g dose was well tolerated in all groups. These data can be used to underwrite nacubactam dosing recommendations for patients with impaired renal function, including those receiving renal replacement therapy.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT02975388.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0011326"},"PeriodicalIF":4.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes of combination versus monotherapy in <i>Stenotrophomonas maltophilia</i> bacteremia: a retrospective single-center analysis.","authors":"Ming-Hang Tsai, Wei-Ping Chen, Chien-Liang Chen, L Kristopher Siu, Ching-Mei Yu, Hung-Sheng Shang, Feng-Yee Chang, Jung-Chung Lin, Ya-Sung Yang, Ching-Hsun Wang","doi":"10.1128/aac.01297-25","DOIUrl":"https://doi.org/10.1128/aac.01297-25","url":null,"abstract":"<p><p>A combination therapy (CT) is recommended for <i>S. maltophilia</i> infections; however, supporting clinical data are limited. This study aimed to compare the effectiveness and safety of CT and monotherapy (MT) in the treatment of <i>S. maltophilia</i> bacteremia. A total of 292 adult inpatients with monomicrobial <i>S. maltophilia</i> bacteremia who received <i>in vitro</i> active CT or MT for >48 h were included for comparison. Multivariable logistic regression analysis was performed. The primary outcome was 30-day mortality, and the secondary outcomes included in-hospital mortality, microbiological eradication rate, clinical response, recurrent bacteremia, isolation of non-susceptible <i>S. maltophilia</i> isolates, and adverse drug reaction (ADR) occurrence. Thirty-seven patients received CT, and 255 received MT. Overall, the 30-day mortality was 24.0%, and patients treated with CT had lower 30-day mortality than those with MT (10.8% vs 25.9%; <i>P</i> = 0.045). The multivariable regression analysis revealed that CT was an independent protective factor. In addition, sensitivity analyses excluding patients with bacterial co-infections showed a consistent trend. Other outcomes were similar between the groups: in-hospital mortality (37.8% vs 36.9%, <i>P</i> = 0.909), clinical response (73.0% vs 71.8%, <i>P</i> = 0.879), microbiological eradication rate (94.6% vs 93.0%, <i>P</i> = 1.000), recurrent bacteremia (0% vs 9.4%, <i>P</i> = 0.087), non-susceptible <i>S. maltophilia</i> isolation (24.3% vs 14.9%, <i>P</i> = 0.145), and ADR occurrence (8.1% vs 13.7%, <i>P</i> = 0.441). CT for <i>S. maltophilia bacteremia</i> was associated with improved outcomes and comparable rates of ADRs and resistance emergence; however, randomized trials with larger cohorts are warranted to confirm these findings.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0129725"},"PeriodicalIF":4.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}